Binimetinib

Drug Profile

Binimetinib

Alternative Names: ARRY-162; ARRY-438162; MEK-162; Mitogen activated kinase inhibitor

Latest Information Update: 18 Jan 2017

Price : $50

At a glance

  • Originator Array BioPharma; Dana-Farber Cancer Institute
  • Developer Array BioPharma; German Cancer Research Center; Merck KGaA; Novartis; Pierre Fabre; Seoul National University Hospital; University of Heidelberg
  • Class Amides; Anti-inflammatories; Antineoplastics; Benzimidazoles; Fluorine compounds; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Malignant melanoma
  • Phase III Colorectal cancer; Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Phase II Haematological malignancies; Multiple myeloma; Non-small cell lung cancer; Solid tumours
  • Phase I/II Acute myeloid leukaemia; Biliary cancer; Chronic myeloid leukaemia; Pancreatic cancer; Uveal melanoma
  • Discontinued Rheumatoid arthritis

Most Recent Events

  • 29 Nov 2016 The University of Utah suspended enrolment in a phase-I trial in Colorectal cancer (Second-line therapy or greater, Late-stage disease, Metastatic disease, Combination therapy) for a protocol amendment to be approved to expand eligibility criteria in USA (PO) (NCT02613650)
  • 21 Nov 2016 Swiss Group for Clinical Cancer Research plans a phase Ib trial for Non-small cell lung cancer Late-stage disease, Metastatic disease) in Switzerland (NCT02964689)
  • 10 Nov 2016 Novartis terminates a phase II trial in Malignant melanoma (Late-stage disease, Metastatic disease, Second-line therapy or greater) in Switzerland, Spain, Germany, Canada, Australia, USA due to scientific and business considerations (PO) (NCT01820364)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top